Quarterly report pursuant to Section 13 or 15(d)

STOCK OPTIONS

v3.10.0.1
STOCK OPTIONS
3 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
11.
STOCK OPTIONS
 
The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company.
 
Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options.
 
On November 24, 2015, the Company granted 650,000 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 250,000 options were cancelled and during the three month period ended June 30, 2018, $35,609 (June 30, 2017
 $35,609) in stock compensation expense was recognized.
 
On December 14, 2015, the Company granted 2,495,000 options to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the years ended March 31, 2016, 2017 and 2018, 25,000 options, 40,000 options and 436,667 options, respectively, were cancelled and for the three month period ended June 30, 2018, $41,350 (June 30, 2017
$100,289) of stock compensation expense was recognized.
 
On April 21, 2016, the Company granted 3,000,000 stock options to employees of Bionik, Inc., the Company’s wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT of which 1,000,000 have an exercise price of $0.25, 1,000,000 have an exercise price of $0.95 and 1,000,000 have an exercise price of $1.05. The grant date fair value of vested options was $2,582,890 and has been recorded as part of the original acquisition equation. The options are fully expensed, and $Nil (June 30, 2017
$10,169) has been recognized as stock compensation expense in the first quarter of 2018.
 
On April 26, 2016, the Company granted 250,000 options to an employee with an exercise price of $1.00 that vest over three years at the anniversary date. The grant fair value was $213,750. During the quarter ended June 30, 2018, $17,813 (June 30, 2017- $17,813) was recognized as stock compensation expense.
 
On August 8, 2016, the Company granted 750,000 options to an employee with an exercise price of $1.00 that vest over three years at the anniversary date. The grant fair value was $652,068. The employee left in April 2018 and 500,000 options that had not vested were cancelled and the remaining 250,000 options will expire in November 2018. During the quarter ended June 30, 2018, $18,113 (June 30, 2017
– 
$54,339) of stock compensation expense was recognized.
 
On February 6, 2017, the Company granted 400,000 options to an employee with an exercise price of $0.70 that vest over three years at the anniversary date. The grant fair value was $245,200. During the quarter ended June 30, 2018, $20,433 (June 30, 2017
$20,433) of stock compensation expense was recognized.
 
On February 13, 2017, the Company granted 250,000 options to a consultant with an exercise price of $0.68 that vest over one and one-half years, every six months. The grant fair value was $148,750. During the quarter ended June 30, 2018, $12,396 (June 30, 2017
 $12,396) of stock compensation expense was recognized. These options are now fully vested.
 
On August 3, 2017, 1,500,000 options with an exercise price of $0.21 were granted to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 500,000 additional performance options based on meeting sales targets for the years ended March 31, 2018 and 2019. The grant value was $387,209 and $7,546 was expensed as stock compensation in the quarter. The executive left in April 2018 and all of these options were cancelled.
 
On September 1, 2017, the Company granted 12,215,354 options with an exercise price of $0.161 equally to an executive officer and a consultant who is now the Chairman of the Company. Of such options, 2,035,892 have vested and 50% of the remaining options vest on performance goals being met and 50% vest over 5 years. The grant fair value was $1,832,304 and during the quarter ended June 30, 2018, $38,173 in stock compensation expense was recognized.
 
On January 24, 2018, the Company granted 3,640,000 options with an exercise price of $0.155 to employees that vest equally on January 24, 2019, 2020 and 2021, The grant fair value was $491,036 and during the quarter ended June 30, 2018, $39,703 in stock compensation expense was recognized.
 
On April 20, 2018, the Company granted to an executive officer, 6,000,000 options with an exercise price of $0.0649 that vest immediately with a 10-year expiry. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 10 years, expected volatility of 114% and a risk free rate of 1.59%. As these options fully vested on the grant date, $363,714 of stock based compensation was recognized during the quarter.
 
On June 11, 2018, the Company granted to a newly-hired executive officer 750,000 options with an exercise price of $0.0462 that vest over three years from the anniversary of the grant and expire in 7 years. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk free rate of 1.59%. The grant fair value was $30,341 and $562 of stock compensation expense was recognized in the quarter.
 
During the quarter ended June 30, 2018, the Company recorded $595,412 in share-based compensation related to the vesting of stock options (June 30, 2017
 $251,048).
 
The following is a summary of stock options outstanding and exercisable as of June 30, 2018:
 
Exercise Price ($)
   
Number of Options
   
Expiry Date
 
Exercisable Options
 
  0.165       154,134     April 1, 2021     154,134  
  0.23       94,368     June 20, 2021     94,368  
  0.23       1,981,728     July 1, 2021     1,981,728  
  0.23       141,557     February 17, 2022     141,557  
  1.22       400,000     November 24, 2022     266,667  
  1.00       1,936,667     December 14, 2022     1,633,333  
  0.95       111,937     March 28, 2023     111,937  
  1.05       433,027     March 28, 2023     433,027  
  1.00       250,000     April 26, 2023     166,667  
  1.00       250,000     August 8, 2023     250,000  
  0.70       400,000     February 6, 2024     133,333  
  0.68       250,000     February 13, 2024     250,000  
  0.95       31,620     March 3, 2024     31,620  
  1.05       122,324     March 3, 2024     122,324  
  0.95       6,324     March 14, 2024     6,324  
  1.05       24,465     March 14,2024     24,465  
  0.95       72,727     September 30, 2024     72,727  
  1.05       281,345     September 30, 2024     281,345  
  0.95       3,478     June 2, 2025     3,478  
  1.05       13,456     June 2, 2025     13,456  
  0.25       66,298     December 30, 2025     66,298  
  0.95       49,160     December 30, 2025     27,261  
  0.161       12,215,354     September 1, 2027     2,035,892  
  0.155       3,365,000     January 24, 2025     -  
  0.0649       6,000,000     April 19, 2028     6,000,000  
  0.0462       750,000     June 10, 2025     -  
          29,404,696           14,301,941  
 
The weighted-average remaining contractual term of the outstanding options was 7.89 (March 31, 2018 – 5.81) and for the options that are exercisable the weighted average was 7.38 (March 31, 2018 – 5.70)